Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > British Columbia Securities Commission!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Feb 07, 2023 2:14pm
171 Views
Post# 35272422

RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!

RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!***What will Rathjen's next move be? ***

Most of us are hoping DrDR will step down and allow Bioasis to seek a new CEO with a more productive approach around its business and its science.

Morally she should should do just that,,,,be honourable and accept that she has performed at the low end of our technolgy advancement scale. Why wouldnt one want to step down???,,and pass the reigns over for the BoDs to secure another competent person.

What we have here is, a CEO, of a Canadian Company, with its head office in the USA, and who's presence is in Aussiland, where by the way Carina Biotech resides!!

It would appear that as CEO she/they has become part of the infamous,,,"Peter Principle"!!

The responsibility of the Team and the BoDs at this very time in our history is to safeguard the comapny's assets so that Bioasis and its shareholders can continue the struggle.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities